Stayble Therapeutics ABFRA:4K4 28 EV-to-FCF is -2.51 as of Jul. 08, 2026. GuruFocus rates FRA:4K4 with a GF Score™ of 28/100. The stock has 1 warning sign investors should review. Among 327 Biotechnology companies, Stayble Therapeutics AB ranks worse than 305810.09% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Stayble Therapeutics AB's Enterprise Value is €1.36 Mil.
Stayble Therapeutics AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.54 Mil. Therefore, Stayble Therapeutics AB's EV-to-FCF for today is -2.51.
The historical rank and industry rank for Stayble Therapeutics AB's EV-to-FCF or its related term are showing as below:
FRA:4K4'
s EV-to-FCF Range Over the Past 10 Years
Min: -2 Med: 0 Max: 0
Current: -2
FRA:4K4's EV-to-FCF is ranked worse than 100% of 327
companies
in the Biotechnology industry
Industry Median: 16.69
vs FRA:4K4: -2.00
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Stayble Therapeutics AB (FRA:4K4) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Stayble Therapeutics AB's PE Ratio (TTM) for today is calculated as:
Stayble Therapeutics AB's share price for today is €0.023.
Stayble Therapeutics AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.016.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Stayble Therapeutics AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stayble Therapeutics AB EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Stayble Therapeutics AB's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Stayble Therapeutics AB's EV-to-FCF falls into.
Stayble Therapeutics AB's current Enterprise Value is €1.36 Mil.
Stayble Therapeutics AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.54 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stayble Therapeutics AB (FRA:4K4) has a EV-to-FCF of -2.51 as of Jul. 08, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Stayble Therapeutics AB and its competitors. According to the industry distribution chart, Stayble Therapeutics AB ranks #999999 out of 327 companies in the Biotechnology industry.
Is Stayble Therapeutics AB's EV-to-FCF too high?
Stayble Therapeutics AB's current EV-to-FCF is -2.51. Based on the distribution chart, Stayble Therapeutics AB ranks #999999 out of 327 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Stayble Therapeutics AB has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Stayble Therapeutics AB's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Stayble Therapeutics AB ranks #999999 out of 327 companies for EV-to-FCF. This places Stayble Therapeutics AB in the lower half of its industry. The industry median EV-to-FCF is 16.69. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.69, based on 327 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Stayble Therapeutics AB and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stayble Therapeutics AB's current EV-to-FCF is -2.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stayble Therapeutics AB stock overvalued right now?
Stayble Therapeutics AB (FRA:4K4) has a current EV-to-FCF of -2.51. The current EV-to-FCF is -2.51. Stayble Therapeutics AB's overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Stayble Therapeutics AB (FRA:4K4), the current EV-to-FCF is -2.51 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Stayble Therapeutics AB is a clinical-stage pharmaceutical company developing STA363, an intradiscally injected formulation against chronic discogenic low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and analgesics. The injection is given once and the effect is expected to remain throughout the patient's life and requires minimal rehabilitation. The company's injection treatment, STA363, is expected to correct the underlying cause of disc-related low back pain by affecting the two main causative factors namely instability of the disc and prevention of leakage of inflammatory mediators from the disc center.
28GF Score
Get the complete analysis for FRA:4K4
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4K4 has been successfully added to your 
